NCT03192501Recruiting
iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray
Multicentre Perspective Non-interventional Study of Survival Benefits of iCAGES-guided Therapy in Contrast to Standard Therapy or IHC-guided Therapy for Advanced Cancers
Source: ClinicalTrials.gov · Last updated 25 Jun 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study prospectively evaluates whether the use of iCAGES (integrated CAncer GEnome Score) tool in guiding the treatment of advanced cancers is superior to current standard care or IHC-guided therapy in progress free survival (PFS),overall survival (OS),and improvement of life quality.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 250 (estimated)
- First submitted
- 15 Jun 2017
- Start date
- 1 Jul 2017
- Primary completion date
- 1 Jul 2030
- Lead sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Diseases
- Lung cancer
- NCT number
- NCT03192501
What you commit to
- Study type: Observational
- Planned participants: 250
- From 1 Jul 2017 to the primary completion date, 1 Jul 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any serious concomitant disease that is expected to have an adverse effect on prognosis, including the heart disease that treatment is required, unsatisfactory controlled diabetes and psychiatric disorders.
Other illness
- Previous history of malignant tumors.
Age
- Age \> 70 or \<18 years old.
Other
- Pregnant or lactating female patients.
Who the study is looking for
- Pathological and clinical diagnosis of recurrence / metastatic lung cancer or other advanced cancers.
- There are PACS images available at the Second Affiliated Hospital of Guangzhou Medical University and the collaborated Hospitals.
- The patient is informed consent and signed a written consent.
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The second Affiliated Hospital of Guangzhou Medical University Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.